References
Ginaldi L, De Martinis M et al (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51:364–369
Golay J, Lazzari M et al (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukaemia: further regulation by CD55 and CD59. Blood 98:12:3383–3389
Panayi GS, Hainsworth JD, Looney RJ, Keystone EC (2005) Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin’s lymphoma. Rheumatology 44(Suppl 2):ii18–ii20
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hobi, A., Bihl, T., Fellay, B. et al. The role of the determination of the CD20 antigen through quantitative flow cytometry in complex cases of rheumatoid arthritis treated with anti-TNF-α. Rheumatol Int 26, 1161–1162 (2006). https://doi.org/10.1007/s00296-006-0139-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-006-0139-y